EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Treatment Reviews

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ctrv.2011.10.003PMID 22119437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.

  2011cited by this paper
• Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

  2011cited by this paper
• Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.

  2011cited by this paper
• Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization

  2011cited by this paper
• Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer

  2011cited by this paper
• Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

  2011cited by this paper
• Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

  2011cited by this paper
• A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.

  2011cited by this paper
• Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH

  2011cited by this paper
• A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.

  2011cited by this paper
• Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

  2011cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

  2011cited by this paper
• A review of PARP inhibitors: from bench to bedside.

  2011cited by this paper
• Targeting phosphoinositide 3-kinase signalling in lung cancer.

  2011cited by this paper
• FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

  2011cited by this paper
• Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.

  2011cited by this paper
• Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

  2010cited by this paper
• Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

  2010cited by this paper
• New inhibitors of the mammalian target of rapamycin signaling pathway for cancer

  2010cited by this paper
• Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• KRAS gene mutations in lung cancer: Particulars established and issues unresolved

  2010cited by this paper
• Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

  2010cited by this paper
• A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples

  2010cited by this paper
• Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

  2010cited by this paper
• Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis

  2010cited by this paper
• KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.

  2010cited by this paper
• Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons.

  2010cited by this paper
• Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC).

  2010cited by this paper
• Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

  2010cited by this paper
• Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR).

  2010cited by this paper
• Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.

  2010cited by this paper
• Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

  2010cited by this paper
• A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

  2010cited by this paper
• Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406.

  2010cited by this paper
• Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape

  2010cited by this paper
• Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.

  2010cited by this paper
• Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

  2010cited by this paper
• Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

  2010cited by this paper
• Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

  2010cited by this paper
• PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study.

  2010cited by this paper
• TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy.

  2010cited by this paper
• Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

  2010cited by this paper
• The biology and treatment of EML4-ALK non-small cell lung cancer.

  2010cited by this paper
• Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

  2010cited by this paper
• International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial.

  2010cited by this paper
• Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

  2010cited by this paper
• New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.

  2010cited by this paper
• Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

  2010cited by this paper
• Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

  2010cited by this paper
• Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

  2010cited by this paper
• Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

  2010cited by this paper
• Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

  2010cited by this paper
• Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.

  2010cited by this paper
• Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

  2010cited by this paper
• Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

  2010cited by this paper
• Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).

  2010cited by this paper
• Functional selectivity of EGF family peptide growth factors: implications for cancer.

  2009cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Mutations and Response to Epidermal Growth Factor Receptor Inhibitors

  2009cited by this paper
• Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

  2009cited by this paper
• Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

  2009cited by this paper
• Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.

  2009cited by this paper
• Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.

  2009cited by this paper
• The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS

  2009cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

  2009cited by this paper
• Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy

  2009cited by this paper
• EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases

  2009cited by this paper
• Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

  2009cited by this paper
• Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer

  2009cited by this paper
• Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

  2009cited by this paper
• Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

  2009cited by this paper
• EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer

  2009cited by this paper
• HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

  2009cited by this paper
• Detection of epidermal growth factor receptor mutations in plasma by mutant‐enriched PCR assay for prediction of the response to gefitinib in patients with non‐small‐cell lung cancer

  2009cited by this paper
• The role of fibroblast growth factors in tumor growth.

  2009cited by this paper
• Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors

  2009cited by this paper
• Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?

  2009cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  2009cited by this paper
• MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

  2009cited by this paper
• Are RAS mutations predictive markers of resistance to standard chemotherapy?

  2009cited by this paper
• MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

  2008cited by this paper
• The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

  2008cited by this paper
• Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

  2008cited by this paper
• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

  2008cited by this paper
• Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study

  2008cited by this paper
• Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

  2008cited by this paper
• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  2008cited by this paper
• Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

  2008cited by this paper

• RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR‐targeted therapies

  2025cites this paper
• WITHDRAWN: OncoStratifier: Stratifying Oncogene-addicted Cohorts By Drug Response

  2025cites this paper
• Correlation analysis between EGFR gene mutation status, ALK positivity and demographic data, tumor biomarkers, radiological and pathological features in patients with lung adenocarcinoma

  2025cites this paper
• Current progress of 1,2,3-triazole hybrids as EGFR inhibitors for cancer therapy – a literature review

  2025cites this paper
• BDTX-189, a novel tyrosine kinase inhibitor, inhibits cell activity via ERK and AKT pathways in the EGFR C797S triple mutant cells.

  2024cites this paper
• Drug Delivery Systems of Gefitinib for Improved Cancer Therapy: A Review

  2023cites this paper
• A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma

  2023cites this paper
• Recent advances in non-small cell lung cancer targeted therapy; an update review

  2023cites this paper
• Integrating network pharmacology and experimental verification to investigate the pharmacological mechanisms of Buzhong Yiqi decoction in the treatment of non‐small cell lung cancer

  2023cites this paper
• Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway.

  2023cites this paper
• MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells

  2022cites this paper
• Generation of genetically engineered mice for lung cancer with mutant EGFR.

  2022cites this paper
• Auxiliary Diagnosis of Lung Cancer with Magnetic Resonance Imaging Data under Deep Learning

  2022cites this paper
• Spoken and Unspoken Matters Regarding the Use of Opioids in Cancer

  2022cites this paper
• Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer

  2022influential citation
• Comparison of the radiomics-based predictive models using machine learning and nomogram for epidermal growth factor receptor mutation status and subtypes in lung adenocarcinoma

  2022cites this paper
• Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients

  2021cites this paper
• Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells

  2021cites this paper
• Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response

  2021cites this paper
• BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level

  2021cites this paper
• Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2

  2020cites this paper
• Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features

  2020cites this paper
• Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data

  2020cites this paper
• EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma

  2019cites this paper
• Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.

  2019cites this paper
• Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data

  2019cites this paper
• Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.

  2018cites this paper
• LXR ligands induce apoptosis of EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt-NF-κB activation

  2018cites this paper
• Synthesis and Preliminarily Cytotoxicity to A549, HCT116 and MCF-7 Cell Lines of Thieno[2,3-d]pyrimidine Derivatives Containing Isoxazole Moiety

  2018influential citation
• Napsin A is negatively associated with EMT‑mediated EGFR‑TKI resistance in lung cancer cells.

  2018cites this paper
• Clinical efficacy of icotinib in patients with advanced nonsquamous non-small cell lung cancer with unknown EGFR mutation status that failed to respond to second-line chemotherapy.

  2018cites this paper
• Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation.

  2018cites this paper
• Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials

  2018cites this paper
• Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2

  2018cites this paper
• Overexpression of Napsin A resensitizes drug-resistant lung cancer A549 cells to gefitinib by inhibiting EMT.

  2018cites this paper
• Autophagy determines osimertinib resistance through regulation of stem cell-like properties in EGFR-mutant lung cancer

  2018cites this paper
• The Frequency of EGFR and KRAS Mutations in the Turkish Population with Non-small Cell Lung Cancer and their Response to Erlotinib Therapy

  2018cites this paper
• Complexity of Delivering Precision Medicine: Opportunities and Challenges.

  2018cites this paper
• Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.

  2017cites this paper
• Non-small cell lung cancer - mutations, targeted and combination therapy.

  2017cites this paper
• A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants.

  2017cites this paper
• Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?

  2017cites this paper
• Studies on epithelial mesenchymal transition (EMT) in 'smoking related' airway disease

  2017influential citation
• High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer

  2017cites this paper
• High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR 1-overexpressing Lung Cancer Running Title : scFv-Fc for Targeting FGFR 1-positive Lung Cancer Cells

  2017cites this paper
• Combinational strategies of metformin and chemotherapy in cancers

  2016cites this paper
• Hedgehog pathway maintains cell survival under stress conditions, and drives drug resistance in lung adenocarcinoma

  2016influential citation
• Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice

  2016cites this paper
• Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non‐small‐cell lung cancer cells

  2016cites this paper
• miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13

  2016cites this paper
• Signalisation nucléaire de l'IGF-1R et résistance aux thérapies anti-EGFR dans les cancers du poumon

  2016cites this paper
• Ovarian metastasis from non-small cell lung cancer with ALK and EGFR mutations: A report of two cases

  2016cites this paper
• Design and Synthesis of Some Novel Estrogen Receptor Modulators as Anti-Breast Cancer Agents: In Vitro & In Vivo Screening, Docking Analysis.

  2016cites this paper
• Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib.

  2016cites this paper
• Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations

  2015cites this paper
• ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer

  2015cites this paper
• Efficient Generation of Mice with Consistent Transgene Expression by FEEST

  2015cites this paper
• Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer

  2015cites this paper
• Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis

  2015cites this paper
• Mouse Models of Cancer

  2015cites this paper
• Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

  2015cites this paper
• Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line

  2015cites this paper
• Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway

  2015influential citation
• QSAR based model for discriminating EGFR inhibitors and non-inhibitors using Random forest

  2015cites this paper
• Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells

  2015cites this paper
• Alectinib in RET-rearranged non-small cell lung cancer-Another progress in precision medicine?

  2015cites this paper
• Promise and challenges on the horizon of MET-targeted cancer therapeutics.

  2015cites this paper
• Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer

  2015cites this paper
• Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.

  2015cites this paper
• Biomarkers for personalized oncology: recent advances and future challenges.

  2015cites this paper
• Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells

  2015cites this paper
• Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.

  2015cites this paper
• Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.

  2015cites this paper
• Umbrella Test the effect of one or more drugs on one or more single mutations in a variety of cancer types Test the impact of different drugs on different mutations in a single type of cancer Basket

  2015cites this paper
• Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update

  2015cites this paper
• MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer

  2015cites this paper
• Synthesis and Biological Evaluation of Quinazoline Derivatives as Potential Anticancer Agents (II).

  2015cites this paper
• The role of epidermal growth factor receptor in non-small cell lung cancer

  2015influential citation
• Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results

  2015cites this paper
• Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome.

  2015cites this paper
• Practical use of advanced mouse models for lung cancer.

  2015cites this paper
• Translation: Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer

  2015cites this paper
• Epidermal Growth Factor Receptor Mutation-Positive Non–Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study

  2015influential citation
• Mechanistic Understanding of Translational Pharmacokinetic-Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase

  2015cites this paper
• Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.

  2014cites this paper
• Nrf2在EGFR基因突变肺腺癌中的表达及其与EGFR-TKIs疗效间的相关性研究

  2014cites this paper
• Precision treatment for cancer: Role of prognostic and predictive markers

  2014cites this paper
• Timing of Metabolic Response Monitoring During Erlotinib Treatment in Non–Small Cell Lung Cancer

  2014influential citation
• Epidermal growth factor receptor inhibitors: coming of age.

  2014cites this paper
• Potential anticancer agents. I. Synthesis of isoxazole moiety containing quinazoline derivatives and preliminarily in vitro anticancer activity.

  2014cites this paper
• Translational Pharmacokinetic-Pharmacodynamic Modeling for An Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros

  2014cites this paper
• The changing world of oncology drug development-A global pharmaceutical company's perspective.

  2014cites this paper
• Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal

  2014cites this paper
• The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro

  2014cites this paper
• A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition

  2014cites this paper
• Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1

  2014cites this paper
• cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?

  2014cites this paper
• Translational Modeling for An Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros

  2014cites this paper
• In Silico Screening of Mutated K-Ras Inhibitors from Malaysian Typhonium flagelliforme for Non-Small Cell Lung Cancer

  2014cites this paper
• ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition

  2014cites this paper